RxDoctor Payments Data

Jessica Thomas, PA

Physician Assistant · Grand Rapids, MINPI 1215523394

Payments from drug & device makers

$2,412in general payments, 2019–2025

Across 66 payments — averaging $36.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$745
  • Xeris Pharmaceuticals, Inc.$615
  • Medtronic$240
  • Dexcom, Inc.$213
  • Novo Nordisk$185
  • Tandem Diabetes Care, Inc.$179
  • plus $233 from 2 others

What the payments were for

  • Food & beverage$2,412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,412 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$16,571
Medicare patients
109
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide226$269,923
OzempicSemaglutide42$74,335
TrulicityDulaglutide54$71,037
JardianceEmpagliflozin47$60,638
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$48,063
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog45$27,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog150$24,029
Humalog Kwikpen U-100Insulin Lispro45$18,465
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$18,054
HumalogInsulin Lispro52$17,285
Lyumjev Kwikpen U-100Insulin Lispro-Aabc17$16,696
Novolog FlexpenInsulin Aspart45$12,035
NovologInsulin Aspart21$11,791
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$8,904
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic37$5,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$56$360,514351 claims
Novo NordiskOzempic, Novolog$185$86,12663 claims
Boehringer IngelheimJardiance$745$60,63847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →